146 related articles for article (PubMed ID: 24143812)
1. Breaking the limits of artificial ubiquitination.
Putyrski M; Dikic I
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17606-7. PubMed ID: 24143812
[No Abstract] [Full Text] [Related]
2. Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.
Haj-Yahya M; Fauvet B; Herman-Bachinsky Y; Hejjaoui M; Bavikar SN; Karthikeyan SV; Ciechanover A; Lashuel HA; Brik A
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17726-31. PubMed ID: 24043770
[TBL] [Abstract][Full Text] [Related]
3. Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
Galesic A; Pratt MR
Methods Mol Biol; 2020; 2133():313-326. PubMed ID: 32144674
[TBL] [Abstract][Full Text] [Related]
4. Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated α-synuclein.
Hejjaoui M; Haj-Yahya M; Kumar KS; Brik A; Lashuel HA
Angew Chem Int Ed Engl; 2011 Jan; 50(2):405-9. PubMed ID: 21154793
[No Abstract] [Full Text] [Related]
5. Sins of synuclein.
Leslie M
Sci Aging Knowledge Environ; 2005 Apr; 2005(16):nf30. PubMed ID: 15843690
[No Abstract] [Full Text] [Related]
6. [Progress in alpha-synuclein modifications and Parkinson's disease].
Ma KL; Chen NH
Sheng Li Ke Xue Jin Zhan; 2010 Oct; 41(5):379-82. PubMed ID: 21416932
[No Abstract] [Full Text] [Related]
7. Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.
Meier F; Abeywardana T; Dhall A; Marotta NP; Varkey J; Langen R; Chatterjee C; Pratt MR
J Am Chem Soc; 2012 Mar; 134(12):5468-71. PubMed ID: 22404520
[TBL] [Abstract][Full Text] [Related]
8. Sequestration of a β-hairpin for control of α-synuclein aggregation.
Mirecka EA; Shaykhalishahi H; Gauhar A; Akgül Ş; Lecher J; Willbold D; Stoldt M; Hoyer W
Angew Chem Int Ed Engl; 2014 Apr; 53(16):4227-30. PubMed ID: 24623599
[TBL] [Abstract][Full Text] [Related]
9. Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.
Redeker V; Pemberton S; Bienvenut W; Bousset L; Melki R
J Biol Chem; 2012 Sep; 287(39):32630-9. PubMed ID: 22843682
[TBL] [Abstract][Full Text] [Related]
10. Conformational ensemble of human α-synuclein physiological form predicted by molecular simulations.
Rossetti G; Musiani F; Abad E; Dibenedetto D; Mouhib H; Fernandez CO; Carloni P
Phys Chem Chem Phys; 2016 Feb; 18(8):5702-6. PubMed ID: 26553504
[TBL] [Abstract][Full Text] [Related]
11. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
[TBL] [Abstract][Full Text] [Related]
12. Preparation of distinct ubiquitin chain reagents of high purity and yield.
Dong KC; Helgason E; Yu C; Phu L; Arnott DP; Bosanac I; Compaan DM; Huang OW; Fedorova AV; Kirkpatrick DS; Hymowitz SG; Dueber EC
Structure; 2011 Aug; 19(8):1053-63. PubMed ID: 21827942
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway.
Tofaris GK; Kim HT; Hourez R; Jung JW; Kim KP; Goldberg AL
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17004-9. PubMed ID: 21953697
[TBL] [Abstract][Full Text] [Related]
14. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.
Rekas A; Lo V; Gadd GE; Cappai R; Yun SI
Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892
[TBL] [Abstract][Full Text] [Related]
15. Engineering and structural characterization of a linear polyubiquitin-specific antibody.
Matsumoto ML; Dong KC; Yu C; Phu L; Gao X; Hannoush RN; Hymowitz SG; Kirkpatrick DS; Dixit VM; Kelley RF
J Mol Biol; 2012 May; 418(3-4):134-44. PubMed ID: 22227388
[TBL] [Abstract][Full Text] [Related]
16. Interaction of prolyl oligopeptidase with α-synuclein.
Lambeir AM
CNS Neurol Disord Drug Targets; 2011 May; 10(3):349-54. PubMed ID: 21222624
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
[TBL] [Abstract][Full Text] [Related]
18. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review.
Gonzalez-Horta A
Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123
[TBL] [Abstract][Full Text] [Related]
19. Lipids as the key to understanding α-synuclein behaviour in Parkinson disease.
Stok R; Ashkenazi A
Nat Rev Mol Cell Biol; 2020 Jul; 21(7):357-358. PubMed ID: 32203270
[No Abstract] [Full Text] [Related]
20. A proof-of-concept study in engineering synthetic protein for selective recognition of substrate-free polyubiquitin.
Xiong Y; Zeng L; Liu W
Proteomics; 2016 Jul; 16(14):1949-51. PubMed ID: 27273999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
